Intracellular accumulation of efavirenz and nevirapine is independent of P-glycoprotein activity in cultured CD4 T cells and primary human lymphocytes

Journal of Antimicrobial Chemotherapy

Volumn 64, Issue 5, 2009, Pages

  Janneh, Omar ^a,b   Chandler, Becky ^b   Hartkoorn, Ruben ^b   Kwan, Wai San ^b   Jenkinson, Claire ^b   Evans, Sorcha ^b   Back, David J ^b   Owen, Andrew ^b   Khoo, Saye H ^b  

^a Faculty of Engineering and Computing   (United Kingdom)

^b UNIVERSITY OF LIVERPOOL   (United Kingdom)

Author keywords

MRP; SLCO OATP; Transport

Indexed keywords

CYTOCHROME P450; CYTOCHROME P450 1B1; CYTOCHROME P450 1B3; CYTOCHROME P450 2B1; CYTOCHROME P450 3A1; CYTOCHROME P450 4A1; DIPYRIDAMOLE; EFAVIRENZ; ELACRIDAR; ESTRONE SULFATE; FUROSEMIDE; GLYCOPROTEIN P; MONTELUKAST; MULTIDRUG RESISTANCE PROTEIN 1; MULTIDRUG RESISTANCE PROTEIN 2; NEVIRAPINE; OCTANOL; ORGANIC ANION TRANSPORTER 1; SODIUM CHLORIDE; TARIQUIDAR; UNCLASSIFIED DRUG; VERLUKAST; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; BENZOXAZINE DERIVATIVE;

ARTICLE; CD4+ T LYMPHOCYTE; CELL TRANSPORT; CELL TYPE; CONTROLLED STUDY; DRUG ACCUMULATION; DRUG UPTAKE; HUMAN; HUMAN CELL; LIPOPHILICITY; PERIPHERAL BLOOD MONONUCLEAR CELL; POLYMERASE CHAIN REACTION; PROTEIN EXPRESSION; PROTEIN FUNCTION; RNA ISOLATION; CELL CULTURE; CELL LINE; CHEMISTRY; CYTOSOL; DRUG EFFECT; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; METABOLISM; MONONUCLEAR CELL;

ANTI-HIV AGENTS; BENZOXAZINES; CD4-POSITIVE T-LYMPHOCYTES; CELL LINE; CELLS, CULTURED; CYTOSOL; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; HUMANS; LEUKOCYTES, MONONUCLEAR; NEVIRAPINE; P-GLYCOPROTEIN;

EID: 73949149076     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkp335     Document Type: Article

References (15)

1. Janneh O, Owen A, Chandler B et al. Modulation of the intracellular accumulation of saquinavir in peripheral blood mononuclear cells by inhibitors of MRP1, MRP2, P-gp and BCRP. AIDS 2005; 19: 2097-102.
2. Dirson G, Fernandez C, Hindlet P et al. Efavirenz does not interact with the ABCB1 transporter at the blood-brain barrier. Pharm Res 2006; 23: 1525-32.
3. Janneh O, Hartkoorn RC, Jones E et al. Cultured CD4T cells and primary human lymphocytes express hOATPs: intracellular accumulation of saquinavir and lopinavir. Br J Pharmacol 2008; 155: 875-83.
4. Chandler B, Almond L, Ford J et al. The effects of protease inhibitors and nonnucleoside reverse transcriptase inhibitors on p-glycoprotein expression in peripheral blood mononuclear cells in vitro. J Acquir Immune Defic Syndr 2003; 33: 551-6.
5. Almond LM, Edirisinghe D, Dalton M et al. Intracellular and plasma pharmacokinetics of nevirapine in human immunodeficiency virus-infected individuals. Clin Pharmacol Ther 2005; 78: 132-42.
6. Berruet N, Sentenac S, Auchere D et al. Effect of efavirenz on intestinal P-glycoprotein and hepatic p450 function in rats. J Pharm Pharm Sci 2005; 8: 226-34.
7. Stormer E, von Moltke LL, Perloff MD et al. Differential modulation of P-glycoprotein expression and activity by non-nucleoside HIV-1 reverse transcriptase inhibitors in cell culture. Pharm Resss 2002; 19: 1038-45.
8. Storch CH, Theile D, Lindenmaier H et al. Comparison of the inhibitory activity of anti-HIV drugs on P-glycoprotein. Biochem Pharmacol 2007; 73: 1573-81.
9. Weiss J, Theile D, Ketabi-Kiyanvash N et al. Inhibition of MRP1/ABCC1, MRP2/ABCC2, and MRP3/ABCC3 by nucleoside, nucleotide, and non-nucleoside reverse transcriptase inhibitors. Drug Metab Dispos 2007; 35: 340-4.
10. Huisman MT, Smit JW, Wiltshire HR et al. P-glycoprotein limits oral availability, brain, and fetal penetration of saquinavir even with high doses of ritonavir. Mol Pharmacol 2001; 59: 806-13.
11. Tamai I, Nezu J, Uchino H et al. Molecular identification and characterization of novel members of the human organic anion transporter (OATP) family. Biochem Biophys Res Commun 2000; 273: 251-60.
12. Tanaka R, Hanabusa H, Kinai E et al. Intracellular efavirenz levels in peripheral blood mononuclear cells from human immunodeficiency virus-infected individuals. Antimicrob Agents Chemother 2008; 52: 782-5.
13. Kasim NA, Whitehouse M, Ramachandran C et al. Molecular properties of WHO essential drugs and provisional biopharmaceutical classification. Mol Pharm 2004; 1: 85-96.
14. Almond LM, Hoggard PG, Edirisinghe D et al. Intracellular and plasma pharmacokinetics of efavirenz in HIV-infected individuals. J Antimicrob Chemother 2005; 56: 738-44.
15. Letschert K, Faulstich H, Keller D et al. Molecular characterization and inhibition of amanitin uptake into human hepatocytes. Toxicol Sci 2006; 91: 140-9.